Background and purpose: Amino acid substitutions in GyrA and ParC are associated with resistance to quinolones in Acinetobacter baumannii (A baumannii), but this association is rarely elucidated in Acinetobacter genomic species (AGS) 13TU. This study aims to compare the association of amino acid substitutions in GyrA and ParC with quinolone resistance in A baumannii and AGS 13TU in Taiwan. Methods: Eleven representative strains of A baumannii and 13 strains of AGS 13TU were selected from 402 bacteremic isolates. The sequences of quinolone resistance determining regions of gyrA and parC were determined. Minimal inhibitory concentrations (MICs) of nalidixic acid, ciprofloxacin, levofloxacin and moxifloxacin were determined by agar dilution method. Results: Ser83Leu substitution in GyrA in A baumannii (one strain) was associated with resistance to all tested quinolones. This substitution plus a Ser80Leu or Ser80Tyr in ParC in A baumannii (four strains) and AGS 13TU (two strains) were associated with higher MICs of all quinolones. All but one quinolone MICs of A baumannii (one strain) and AGS 13TU (two strains) carrying a single substitution Ser56Asn in ParC remained in the susceptibility breakpoint. The Available online at www.sciencedirect.com j ourna l home pa ge: www.e-jmii.com
Introduction
Acinetobacter species, especially A baumannii, Acinetobacter genomic species (AGS) 3 and 13TU, have emerged as important pathogens of nosocomial infection with high mortality and morbidity in critically ill patients.
1,2 They also cause outbreaks in intensive care units and are difficult to eradicate because of their ability to survive in harsh environments for a prolonged time. 3 With their ability to accumulate different mechanisms of resistance and increasing numbers of more vulnerable hosts, the prevalence of multidrug resistant Acinetobacter spp. has been rising in the past decades and the choice of treatment has become limited. 4, 5 Although they are phenotypically undifferentiated, they have distinct resistance mechanisms for antimicrobial agents. As for resistance to aminoglycosides, A baumannii carries armA and aph(3 0 )-Ia, whereas AGS 13TU possesses aac(3)-Ia and aph(3 0 )-VI. 6 For resistance to carbapenems, bla IMP-1 and bla , which belong to class B metallo-beta-lactamase genes, are more commonly found in AGS 13TU, and the class D carbapenemase genes are observed more often in A baumannii. 7 Quinolones have been used for the treatment of Acinetobacter spp. because of their good activity, even compared with broad-spectrum cephalosporins and aminoglycosides, until a high rate of resistance to quinolones was detected recently.
8e10 Three mechanisms of resistance to quinolones have been recognized: (1) mutations in target enzymes; (2) changes in drug entry and efflux; and (3) plasmid-mediated Qnr protein, which prevents DNA from quinolone binding and compromises the efficacy of quinolones. 11e13 The most commonly identified mechanism in Gram-negative bacilli is mutations in target enzymes including DNA gyrase, encoded by gyrA and gyrB, and topoisomerase IV, encoded by parC and parE. In A baumannii, rapid resistance to ciprofloxacin and nalidixic acid is associated with the chromosomal mutations in the quinolone resistance determining regions (QRDRs) of gyrA and/or parC. 4, 5, 8, 9, 14 Single amino acid substitution in GyrA (Ser83Leu) is associated with high level resistance to ciprofloxacin and nalidixic acid. 4, 5, 9 An additional amino acid substitution in ParC, mostly Ser80Leu, is associated with higher resistance in A baumannii. 8, 9, 14 To date, the majority of the data regarding quinolone resistance focused on A baumannii. 4, 5, 8, 9, 14 In contrast, the mechanism of quinolone resistance in AGS 13TU, which is genetically closely related to and phenotypically undifferentiated from A baumannii, 3 is not elucidated. Recent studies showed that A baumannii and AGS 13TU possess remarkably distinct phenotypic and genotypic traits against antimicrobial agents.
15, 16 Lee et al reported A baumannii bacteremia was associated with a higher 14-day mortality rate, a higher 30-day mortality rate and a higher in-hospital mortality rate than bacteremia due to AGS 13TU or 3. 17 Chuang et al revealed higher rates of antimicrobial resistance and poorer outcome for patients infected with A baumannii than for those infected with AGS 13TU or 3. 18 The prevalence of resistance to ciprofloxacin was different in these studies, but the mechanism was not analyzed. The major aim of the present study was to compare the association of amino acid substitutions in GyrA and ParC with quinolone resistance between the clinical isolates of A baumannii and AGS 13TU in Taiwan.
Materials and methods

Bacterial strains and antimicrobial susceptibility testing
During 2006 and 2008, 402 bacteremic isolates of Acinetobacter spp. were collected. Twenty-four representative strains of Acinetobacter spp. with different susceptibility to quinolones and pulsotypes were selected for the study. All strains had been identified to the genomic species level by either a multiplex PCR method 19 or sequencing analysis of 16S-23S rRNA internal transcribed spacer. 20 Susceptibility against nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin were established by the agar dilution method recommended by the Clinical and Laboratory Standards Institute (CLSI). 21 The breakpoints proposed by CLSI were used for nalidixic acid (susceptible 16 mg/mL; resistant ! 32 mg/mL), 22 ciprofloxacin (susceptible 1 mg/mL; resistant ! 4 mg/mL) and levofloxacin (susceptible 2 mg/mL; resistant ! 8 mg/ mL). 21 The breakpoint of moxifloxacin (susceptible 1 mg/ mL; resistant ! 4 mg/mL) was proposed by the manufacturer.
Amplification and DNA sequencing of the QRDRs of the gyrA and parC
The QRDRs of gyrA and parC were amplified with the following primer pairs: 5 0 -atgagcgtatcggaaatccg-3 0 and 5 0 -ggtatttaccacgaatgtgtaa-3 0 for gyrA, and 5 0 -atgaccagcctt gcgcatc-3 0 and 5 0 -gttatcttgccattcgctagt-3 0 for parC with a proof-reading polymerase (Takara Bio Inc, Otsu, Shiga, Japan), yielding amplicons of 733 and 450 base pairs, respectively. Polymerase chain reaction (PCR) program was as follows: 94 C for 1 minute, 35 cycles at 98 C for 10 seconds, and 60 C for 1 minute with a final extension at 72 C for 10 minutes. The amplified DNA product was resolved by electrophoresis in agarose 2% w/v gels, stained with ethidium bromide, and purified according to the manufacturer's instruction (Geneaid Biotech Ltd, Taipei, Taiwan). The purified PCR product was cloned into a pCRII-TOPO Ò vector and transformed into Escherichia coli (Invitrogen Corp., Carlsbad, CA, USA). The sample was then processed for DNA sequencing (Mission Biotech, Taipei, Taiwan).
Results
A total of 24 representative strains comprising A baumannii (11 strains) and AGS 13TU (13 strains) were included in the study. The amino acid substitutions in the QRDRs of the GyrA and ParC of these strains and their association with quinolone MICs were presented.
For A baumannii, five strains (strain number 16, 129, 202, 312, 305) had mutation on QRDRs of gyrA, leading to an amino acid Ser83Leu substitution ( 
Discussion
Among Acinetobacter spp., A baumannii and AGS 13TU are the most clinically relevant pathogens of nosocomial infections. 23 They have different clinical features, outcomes and resistance rates to several antibiotics, 17 including fluoroquinolones. In Sheng's study, 24 as compared with carbapenem-resistant A baumannii, carbapenem-resistant AGS 13TU and 3 isolates have higher antimicrobial susceptible rates to ciprofloxacin. It is well-known that, for resistance to quinolones, amino acid substitutions in GyrA and ParC play important roles in Gram-negative bacilli. 25 The contribution of amino acid substitutions in GyrA and ParC to quinolone resistance may be unequal among different Gram-negative bacilli. In Pseudomonas aeruginosa, the fluoroquinolone resistance is mainly due to gyrA mutations, with parC mutations being less significant. 26 Double mutations in gyrA and parC were needed for high level resistance to quinolones in A baumannii, but three or four mutations in both gyrA and parC genes are required for high-level resistance to ciprofloxacin in E coli. 8, 27, 28 Therefore, our study compared the association of amino acid substitutions in GyrA and ParC with quinolone resistance in the two most clinically important Acinetobacter spp., A baumannii and AGS 13TU.
Our study revealed that the association of amino acid substitutions of GyrA and ParC with quinolone resistance in A baumannii and AGS 13TU was largely similar, with only a mild discrepancy. Single amino acid Ser83Leu substitution in GyrA was associated with high level MICs of all quinolones in A baumannii, but only associated with a high level of MIC of nalidixic acid in AGS 13TU. Further substitution in ParC (Tables 1 and 2 ). These mechanisms resembled those in other Gram-negative bacilli. 8, 9, 14 This study also demonstrated that newer fluoroquinolones were less influenced by amino acid substitutions in GyrA and ParC in Acinetobacter. 14, 29 This may be partially explained by the intrinsic structure of different quinolones.
12,30e32 Unexpectedly, with s similar Ser83Leu substitution in GyrA, A baumannii became more resistant than AGS 13TU to newer fluoroquinolones. If this result can be demonstrated in more strains, it may be one of the reasons to explain the higher rate of resistance to quinolones in A baumannii than AGS 13TU.
To the best of our knowledge, a novel substitution in ParC 56 was found in Acinetobacter in the current study. Substitutions of ParC at Ser80 and Glu84 have been previously detected and contribute to MIC change in A. baumannii. Chiu et al 33 observed a novel parC gene mutation leading to amino acid substitution, Lys59Gln. In the absence of concurrent amino acid substitution in GyrA, the Lys59Gln in ParC was associated with ciprofloxacin resistance. The result disclosed that in A baumannii substitution of ParC might be as important as substitution of GyrA. However, a high level of expression of AdeB, an efflux pump protein, was found in the resistant strain. Thus, the author suggested that ParC Lys59Gln mutation and the efflux pump may function synergistically to induce resistance to ciprofloxacin. In our study, substitution in ParC, without substitution in GyrA, were noted both in A baumannii and AGS 13TU. Although the substitution was not associated with significant MIC change in strain 514 of A baumannii and strain 502 of AGS 13TU, the MICs of nalidixic acid and ciprofloxacin in strain 23 of AGS 13TU increased (MIC of 16 mg/mL for nalidixic acid and 4 mg/mL for ciprofloxacin). It implied that in AGS 13TU, ParC may be more than a secondary target, although the synergistic role should also be considered.
In conclusion, A baumannii and AGS 13TU possess similar substitutions in QRDRs in GyrA and ParC that are associated with quinolone resistance. Single substitution Ser83Leu at GyrA could confer high level resistance to quinolones in A baumannii, but may not confer high level resistance to newer fluoroquinolones in AGS 13TU. An additional substitution at ParC 80 was associated with a higher level of resistance to quinolones in both Acinetobacter spp. The role of substitution at ParC 56 needs to be further elucidated. 
